Literature DB >> 28776686

Contralateral R1 and R2 components of the laryngeal adductor reflex in humans under general anesthesia.

Catherine F Sinclair1, Maria J Téllez2, Oscar R Tapia2, Sedat Ulkatan1.   

Abstract

OBJECTIVES: To demonstrate that under total intravenous general anesthesia (TIVA), the contralateral R1 (cRI) and contralateral R2 (cR2) components of the laryngeal adductor reflex (LAR) can be reliably elicited; to determine effects of topical anesthesia and inhalational anesthesia on the LAR; and to discuss how this technique may be utilized to continuously monitor the vagus nerve reflex arc. STUDY
DESIGN: Case series.
METHODS: Vocal fold mucosa was electrically stimulated via endotracheal tube surface-based electrodes to elicit a LAR. Responses were recorded using the endotracheal tube electrode contralateral to the simulating electrode for each side.
RESULTS: Twenty-one patients (31 nerves at risk), aged between 28 to 84 years, who underwent thyroid and cervical spine surgeries (4 males, 17 females) were included. cR1 responses were reliably elicited in all patients, and cR2 responses were obtained in 14 patients (66.6%). Mean cR1 latencies ± standard deviation were 22.5 ± 2.5 milliseconds (ms) (left) and 23.4 ± 3.3 ms (right). Mean cR1 amplitudes were 237.9 ± 153.9 microvolts (uV) (left) and 265.0 ± 226.5 uV (right). Mean R2 latencies were 59.8 ± 4.9 ms (left) and 61.8 ± 7.9 ms (right). Intraoperative reversible cR1 amplitude decreases correlated temporally with surgical maneuvers stretching or compressing the RLN or internal branch of the superior laryngeal nerve (iSLN). Inhalational anesthetic agents abolished cR2 and minimized cR1 at mean alveolar concentrations > 0.5. Topical lidocaine significantly reduced LAR amplitude.
CONCLUSION: LAR cR1 and cR2 responses are present in humans under TIVA and may afford some airway protection against aspiration under anesthesia. They are inhibited by inhalational anesthetics and topical lidocaine. Continuous intraoperative iSLN and RLN monitoring are possible using surface-based endotracheal tube electrodes alone to stimulate and record cR1 responses. LEVEL OF EVIDENCE: 4. Laryngoscope, 127:E443-E448, 2017.
© 2017 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Laryngeal adductor reflex; larynx; neurolaryngology; neuromonitoring; recurrent laryngeal nerve; superior laryngeal nerve

Mesh:

Substances:

Year:  2017        PMID: 28776686     DOI: 10.1002/lary.26744

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  5 in total

1.  Droplet applicator module for reproducible and controlled endoscopic laryngeal adductor reflex stimulation.

Authors:  J F Fast; K A Westermann; M-H Laves; M Jungheim; M Ptok; T Ortmaier; L A Kahrs
Journal:  Biomicrofluidics       Date:  2020-08-07       Impact factor: 2.800

2.  Sensory Innervation of the Larynx and the Search for Mucosal Mechanoreceptors.

Authors:  Alexander G Foote; Susan L Thibeault
Journal:  J Speech Lang Hear Res       Date:  2021-01-19       Impact factor: 2.297

3.  Supraglottic Botulinum Toxin Improves Symptoms in Patients with Laryngeal Sensory Dysfunction Manifesting as Abnormal Throat Sensation and/or Chronic Refractory Cough.

Authors:  Daniel Novakovic; Meet Sheth; Thomas Stewart; Katrina Sandham; Catherine Madill; Antonia Chacon; Duy Duong Nguyen
Journal:  J Clin Med       Date:  2021-11-23       Impact factor: 4.241

Review 4.  Intraoperative Neuromonitoring: Evaluating the Role of Continuous IONM and IONM Techniques for Emerging Surgical and Percutaneous Procedures.

Authors:  Catherine McManus; Jennifer Hong Kuo
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-30       Impact factor: 5.555

Review 5.  Intraoperative Neuromonitoring: Evaluating the Role of Continuous IONM and IONM Techniques for Emerging Surgical and Percutaneous Procedures.

Authors:  Pia Pace-Asciak; Jonathon O Russell; Vaninder K Dhillon
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-22       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.